Heart Failure: Recent Advances and Breakthroughs.

Autor: Sebastian SA; Azeezia Medical College, Kollam, Kerala, India. Electronic address: snehaann1991@gmail.com., Co EL; University of Santo Tomas Faculty of Medicine and Surgery, Manila, Philippines., Mahtani A; Richmond University Medical Center/Mount Sinai, Staten Island, New York, USA., Padda I; Richmond University Medical Center/Mount Sinai, Staten Island, New York, USA., Anam M; Deccan College of Medical Sciences, Hyderabad, India., Mathew SS; Wuhan University School of Medicine, PR, China., Shahzadi A; Shalamar Hospital, Lahore, Pakistan., Niazi M; Royal Alexandra Hospital, Edmonton, Canada., Pawar S; Shree Vighanharta Superspecialty Hospital Dhule, India., Johal G; Department of Cardiology, University of Washington, Valley Medical Center, Seattle, Washington, USA.
Jazyk: angličtina
Zdroj: Disease-a-month : DM [Dis Mon] 2024 Feb; Vol. 70 (2), pp. 101634. Date of Electronic Publication: 2023 Sep 12.
DOI: 10.1016/j.disamonth.2023.101634
Abstrakt: Heart failure (HF) is a common clinical condition encountered in various healthcare settings with a vast socioeconomic impact. Recent advancements in pharmacotherapy have led to the evolution of novel therapeutic agents with a decrease in hospitalization and mortality rates in HF with reduced left ventricular ejection fraction (HFrEF). Lately, the introduction of artificial intelligence (AI) to construct decision-making models for the early detection of HF has played a vital role in optimizing cardiovascular disease outcomes. In this review, we examine the newer therapies and evidence behind goal-directed medical therapy (GDMT) for managing HF. We also explore the application of AI and machine learning (ML) in HF, including early diagnosis and risk stratification for HFrEF.
Competing Interests: Declaration of Competing Interest The authors have no competing interests to declare that are relevant to the content of this article.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: